Differential effects of complement activation products C3a and C5a on cardiovascular function in hypertensive pregnant ratss

Journal of Pharmacology and Experimental Therapeutics

Volumn 351, Issue 2, 2014, Pages 344-351

  Lillegard, Kathryn E ^a   Loeks Johnson, Alex C ^a   Opacich, Jonathan W ^a   Peterson, Jenna M ^a   Bauer, Ashley J ^a   Elmquist, Barbara J ^a   Regal, Ronald R ^b   Gilbert, Jeffrey S ^a   Regal, Jean F ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA DULUTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANTIHYPERTENSIVE AGENT; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; N2 [(2,2 DIPHENYLETHOXY)ACETYL]ARGININE; PMX 51; UNCLASSIFIED DRUG; VASCULOTROPIN; COMPLEMENT RECEPTOR; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; FETUS; FETUS WEIGHT; HEART RATE; IN VIVO STUDY; ISCHEMIA; MATERNAL HYPERTENSION; NEUTROPHIL; NONHUMAN; PERFUSION PRESSURE; PLACENTA DISORDER; PRESSOR RESPONSE; PROTEIN BLOOD LEVEL; RAT; VASODILATATION; ANIMAL; CARDIOVASCULAR SYSTEM; DISEASE MODEL; DRUG ANTAGONISM; HYPERTENSION; IMMUNOLOGY; PATHOPHYSIOLOGY; PLACENTA; PREGNANCY; VASCULAR ENDOTHELIUM;

ANIMALS; CARDIOVASCULAR SYSTEM; COMPLEMENT ACTIVATION; COMPLEMENT C3A; COMPLEMENT C5A; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FEMALE; HEART RATE; HYPERTENSION; ISCHEMIA; PLACENTA; PREGNANCY; RATS; RECEPTORS, COMPLEMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84908143789     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.218123     Document Type: Article

References (48)

1. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy (2013) Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol 122:1122-1131.
2. Ames RS, Lee D, Foley JJ, Jurewicz AJ, Tornetta MA, Bautsch W, Settmacher B, Klos A, Erhard KF, Cousins RD, et al. (2001) Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models. J Immunol 166:6341-6348.
3. Ananth CV, Keyes KM, and Wapner RJ (2013) Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis. BMJ 347:f6564.
4. Bauer AJ, Banek CT, Needham K, Gillham H, Capoccia S, Regal JF, and Gilbert JS (2013) Pravastatin attenuates hypertension, oxidative stress, and angiogenic imbalance in rat model of placental ischemia-induced hypertension. Hypertension 61:1103-1110.
5. Björk J, Hugli TE, and Smedegård G (1985) Microvascular effects of anaphylatoxins C3a and C5a. J Immunol 134:1115-1119.
6. Bosmann M, Haggadone MD, Zetoune FS, Sarma JV, and Ward PA (2013) The interaction between C5a and both C5aR and C5L2 receptors is required for production of G-CSF during acute inflammation. Eur J Immunol 43:1907-1913.
7. Burwick RM and Feinberg BB (2013) Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta 34:201-203.
8. Burwick RM, Fichorova RN, Dawood HY, Yamamoto HS, and Feinberg BB (2013) Urinary excretion of C5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy. Hypertension 62:1040-1045.
9. Buurma A, Cohen D, Veraar K, Schonkeren D, Claas FH, Bruijn JA, Bloemenkamp KW, and Baelde HJ (2012) Preeclampsia is characterized by placental complement dysregulation. Hypertension 60:1332-1337.
10. Collard CD, Väkevä A, Morrissey MA, Agah A, Rollins SA, Reenstra WR, Buras JA, Meri S, and Stahl GL (2000) Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol 156:1549-1556.
11. Croker DE, Halai R, Fairlie DP, and Cooper MA (2013) C5a, but not C5a-des Arg, induces upregulation of heteromer formation between complement C5a receptors C5aR and C5L2. Immunol Cell Biol 91:625-633.
12. Derzsy Z, Prohászka Z, Rigó J, Jr, Füst G, and Molvarec A (2010) Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol 47:1500-1506.
13. Ember JA, Johansen NL, and Hugli TE (1991) Designing synthetic superagonists of C3a anaphylatoxin. Biochemistry 30:3603-3612.
14. Finch AM, Wong AK, Paczkowski NJ, Wadi SK, Craik DJ, Fairlie DP, and Taylor SM (1999) Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J Med Chem 42:1965-1974.
15. Fraser DG and Regal JF (1990) C5a/C5ades-Arg-induced increase in blood pressure in the guinea pig: role of thromboxane. Immunopharmacology 19:59-68.
16. Gilbert JS, Banek CT, Bauer AJ, Gingery A, and Dreyer HC (2012a) Placental and vascular adaptations to exercise training before and during pregnancy in the rat. Am J Physiol Regul Integr Comp Physiol 303:R520-R526.
17. Gilbert JS, Banek CT, Bauer AJ, Gingery A, and Needham K (2012b) Exercise training attenuates placental ischemia-induced hypertension and angiogenic imbalance in the rat. Hypertension 60:1545-1551.
18. Gilbert JS, Banek CT, Katz VL, Babcock SA, and Regal JF (2012c) Complement activation in pregnancy: too much of a good thing? Hypertension 60:1114-1116.
19. Gilbert JS, Bauer AJ, Gilbert SA, and Banek CT (2012d) The opposing roles of antiangiogenic factors in cancer and preeclampsia. Front Biosci (Elite Ed) 4:2752-2769
20. Gilbert JS, Bauer AJ, Gingery A, Banek CT, and Chasson S (2012e) Circulating and utero-placental adaptations to chronic placental ischemia in the rat. Placenta 33:100-105.
21. Gilbert JS, Verzwyvelt J, Colson D, Arany M, Karumanchi SA, and Granger JP (2010) Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placental ischemia-induced hypertension. Hypertension 55:380-385.
22. Granger JP, LaMarca BB, Cockrell K, Sedeek M, Balzi C, Chandler D, and Bennett W (2006) Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia. Methods Mol Med 122:383-392.
23. Greene AL, Rutherford MS, Regal RR, Flickinger GH, Hendrickson JA, Giulivi C, Mohrman ME, Fraser DG, and Regal JF (2005) Arginase activity differs with allergen in the effector phase of ovalbumin-versus trimellitic anhydride-induced asthma. Toxicol Sci 88:420-433.
24. Greenwood JP, Scott EM, Stoker JB, Walker JJ, and Mary DA (2001) Sympathetic neural mechanisms in normal and hypertensive pregnancy in humans. Circulation 104:2200-2204.
25. Hines T, Beauchamp D, and Rice C (2007) Baroreflex control of sympathetic nerve activity in hypertensive pregnant rats with reduced uterine perfusion. Hypertens Pregnancy 26:303-314.
26. Kerr H and Richards A (2012) Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome. Immunobiology 217:195-203.
27. Klos A, Wende E, Wareham KJ, and Monk PN (2013) International Union of Basic and Clinical Pharmacology. [corrected]. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol Rev 65:500-543.
28. LaMarca B, Cornelius D, and Wallace K (2013) Elucidating immune mechanisms causing hypertension during pregnancy. Physiology (Bethesda) 28:225-233.
29. Lillegard KE, Bauer AJ, Johnson AC, Lojovich SJ, Gilbert JS, and Regal JF (2013a) Neutrophil depletion attenuates placental ischemia-induced hypertension in rat. FASEB J 27:907.4.
30. Lillegard KE, Johnson AC, Lojovich SJ, Bauer AJ, Marsh HC, Gilbert JS, and Regal JF (2013b) Complement activation is critical for placental ischemia-induced hypertension in the rat. Mol Immunol 56:91-97.
31. Lynch AM and Salmon JE (2010) Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications. Placenta 31:561-567.
32. Mason JC, Steinberg R, Lidington EA, Kinderlerer AR, Ohba M, and Haskard DO (2004) Decay-accelerating factor induction on vascular endothelium by vascular endothelial growth factor (VEGF) is mediated via a VEGF receptor-2 (VEGF-R2) - and protein kinase C-alpha/epsilon (PKCalpha/epsilon)-dependent cytoprotective signaling pathway and is inhibited by cyclosporin A. J Biol Chem 279:41611-41618.
33. Mathieu MC, Sawyer N, Greig GM, Hamel M, Kargman S, Ducharme Y, Lau CK, Friesen RW, O'Neill GP, Gervais FG, et al. (2005) The C3a receptor antagonist SB 290157 has agonist activity. Immunol Lett 100:139-145.
34. Paller MS (1987) Decreased pressor responsiveness in pregnancy: studies in experimental animals. Am J Kidney Dis 9:308-311.
35. Proctor LM, Arumugam TV, Shiels I, Reid RC, Fairlie DP, and Taylor SM (2004) Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury. Br J Pharmacol 142:756-764.
36. Proctor LM, Moore TA, Monk PN, Sanderson SD, Taylor SM, and Woodruff TM (2009) Complement factors C3a and C5a have distinct hemodynamic effects in the rat. Int Immunopharmacol 9:800-806.
37. Proctor LM, Strachan AJ, Woodruff TM, Mahadevan IB, Williams HM, Shiels IA, and Taylor SM (2006) Complement inhibitors selectively attenuate injury following administration of cobra venom factor to rats. Int Immunopharmacol 6:1224-1232.
38. Regal JF (1982) C5a-induced aortic contraction: effect of an antihistamine and inhibitors of arachidonate metabolism. J Pharmacol Exp Ther 220:102-107.
39. Regal JF (1985) Effect of C5a on isolated guinea pig atria. Immunopharmacology 9:27-31.
40. Regal JF, Eastman AY, and Pickering RJ (1980) C5a induced tracheal contraction: a histamine independent mechanism. J Immunol 124:2876-2878.
41. Ricklin D and Lambris JD (2013) Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol 190:3839-3847.
42. Scully CC, Blakeney JS, Singh R, Hoang HN, Abbenante G, Reid RC, and Fairlie DP (2010) Selective hexapeptide agonists and antagonists for human complement C3a receptor. J Med Chem 53:4938-4948.
43. Singh J, Ahmed A, and Girardi G (2011) Role of complement component C1q in the onset of preeclampsia in mice. Hypertension 58:716-724.
44. Soto E, Romero R, Richani K, Espinoza J, Chaiworapongsa T, Nien JK, Edwin SS, Kim YM, Hong JS, Goncalves LF, et al. (2010) Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products. J Matern Fetal Neonatal Med 23:646-657.
45. Usami M, Mitsunaga K, Miyajima A, Sunouchi M, and Doi O (2010) Complement component C3 functions as an embryotrophic factor in early postimplantation rat embryos. Int J Dev Biol 54:1277-1285.
46. Wang W, Irani RA, Zhang Y, Ramin SM, Blackwell SC, Tao L, Kellems RE, and Xia Y (2012) Autoantibody-mediated complement C3a receptor activation contributes to the pathogenesis of preeclampsia. Hypertension 60:712-721.
47. Weissgerber TL, McConico A, Knudsen BE, Butters KA, Hayman SR, White WM, Milic N, Miller VM, and Garovic VD (2014) Methodological differences account for inconsistencies in reported free VEGF concentrations in pregnant rats. Am J Physiol Regul Integr Comp Physiol 306:R796-R803.
48. Wu MC, Brennan FH, Lynch JP, Mantovani S, Phipps S, Wetsel RA, Ruitenberg MJ, Taylor SM, and Woodruff TM (2013) The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization. Proc Natl Acad Sci USA 110:9439-9444.